Polycystic Ovary Syndrome (PCOS) Treatment Market

Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook (2024 to 2034)

The global polycystic ovary syndrome (PCOS) treatment market size is set to stand at a value of US$ 4.33 billion in 2024 and further expand at a CAGR of 4.7% to reach US$ 6.84 billion by the end of 2034.

Polycystic ovary syndrome is a type of disease where several small cysts (fluid-filled sacs) form in the ovaries. Polycystic ovary syndrome is a common health problem that affects women of different ages.

PCOS disease creates an immense uncomfortable and painful situation, and its increasing prevalence is resulting in increased demand for associated treatments. The PCOS treatment market is projected to generate lucrative opportunities for treatment providers, amid increasing awareness of the importance of medical intervention to manage this condition.

Key Market Growth Drivers

• Polycystic ovary syndrome (PCOS) is primarily caused by genetic changes, though research suggests exposure to certain hormones or environmental factors increases the risk of developing PCOS. Women need to monitor these changes and undergo frequent check-ups, driving global demand.
• PCOS affects women across all age groups, providing a significant customer base for treatment suppliers. They formulate strategies to attract a broad spectrum of women and boost sales.
• PCOS progresses in four stages, each requiring different treatments. Market players invest in research to understand these stages and enhance treatment quality for immediate relief.
• An irregular menstrual cycle is a key symptom of PCOS. Many girls seek medical attention upon noticing this symptom, further propelling sales of polycystic ovary syndrome treatments.
• Women are increasingly conscious of their health, actively seeking ways to enhance it and screen for potential health issues, thus driving demand for polycystic ovary syndrome treatments.
• In recent years, women have entered the corporate world, gaining financial independence and a platform to address their concerns. This advancement contributes to polycystic ovary syndrome treatment market growth.

Report Attributes	Details
PCOS Treatment Market Size (2024E)	US$ 4.33 Billion
Forecasted Market Value (2034F)	US$ 6.84 Billion
Global Market Growth Rate (2024 to 2034)	4.7% CAGR
Canada Market Growth Rate (2024 to 2034)	4.5% CAGR
China Market Value (2034F)	US$ 675 Million
North America Market Share (2024E)	31.9%
East Asia Market Share (2034F)	18.8%
Key Companies Profiled	Sanofi Novartis AG Teva Pharmaceutical Industries Limited Addex Therapeutics Ltd. Bristol Myers Squibb Co. Ferring Pharmaceuticals Crinetics Pharmaceuticals AstraZeneca Plc Aphena Pharma Solutions Tennessee, Inc. Lupin Pharmaceuticals Sun Pharmaceutical Industries Ltd.

Which Key Polycystic Ovary Syndrome Treatment Market Trends are Benefitting Providers?

“Focus on Proactive Measures to Prevent, Screen, and Manage PCOS During Reproductive Years”

PCOS is a well-known, lifelong disorder. Thus, it is crucial to advocate for a tailored diagnostic approach and treatment plan at various life stages. According to the latest global PCOS guidelines, proactive measures should be taken to avoid, screen, and manage the condition during a woman's reproductive years. Secondary prevention focuses on early screening of girls at higher risk, while primary interventions recommend healthy lifestyle practices to prevent excessive weight gain.

Treatment interventions also emphasize standardized diagnostic criteria, prompt and accurate diagnosis, enhanced patient and professional education, improved screening and diagnostic procedures, and early intervention for PCOS-related complications. This focus has significantly boosted the sales of polycystic ovary syndrome treatments, as the syndrome frequently affects females, thus contributing to the expansion of the polycystic ovary syndrome treatment market size.

“Increasing Campaigns to Raise Awareness Regarding PCOS”

In recent years, there has been a considerable increase in awareness campaigns for PCOS worldwide.

• For example, the PCOS Awareness Association (PCOSAA) organizes many activities and conferences to raise awareness among the global public. PCOSSA recently recognized September as PCOS Awareness Month and has scheduled several events and activities to raise awareness.

Metformin, clomiphene (Clomid), either alone or in combination, and rosiglitazone are the first-line treatments for PCOS patients looking to promote ovulation and cure infertility. According to anecdotal data, oral contraceptives are one of the most commonly utilized drugs to manage irregular menstruation in PCOS women.

Insulin-sensitizing medicines such as metformin, rosiglitazone, and pioglitazone have been shown to improve fertility and ovulation in PCOS women. This awareness has boosted the demand for polycystic ovary syndrome treatments as females are getting more aware of their health concerns and actively working to improve their health.

What are the Challenges Faced by PCOS Treatment Providers?

“Limited Availability of Medications Specifically Licensed for PCOS Treatment”

Few medications are licensed to address the most common PCOS symptoms, leading individuals to resort to off-label use of drugs intended for other purposes. There have been few randomized or placebo-controlled trials on the efficacy of these medications in treating PCOS symptoms and indications. Due to a lack of alternatives, these medications are often employed when approved therapies fail or when no authorized drug is available for the indication.

There are currently no FDA-approved medications specifically for the treatment of PCOS. Furthermore, there are few medications recommended or licensed for addressing PCOS symptoms such as irregular menstruation, acne, and hirsutism. This poses challenges for producers in developing and marketing treatment options.

Alternative therapeutic methods such as homeopathy and Ayurveda are also available. Many individuals prefer these methods for PCOS treatment due to their benefits and improved outcomes. This presents another obstacle to PCOS treatment market growth. These challenges are restricting market expansion and causing concerns for suppliers regarding their profitability. Market players are investing in research and analysis to address this issue and maintain their presence in the PCOS treatment market.

Country-wise Evaluation

The East Asian market is projected to exhibit growth during the forecast period. The market in Japan is forecasted to expand at a CAGR of 5.5% from 2024 to 2034.

Why is the United States Government Taking Proactive Measures to Combat PCOS?

“Rising Prevalence of Obesity and Insulin Sensitivity Resulting from PCOS”

Attribute	United States
Market Value (2024E)	US$ 1.18 Billion
Growth Rate (2024 to 2034)	4.3% CAGR
Projected Value (2034F)	US$ 1.8 Billion

Several developed countries, particularly the United States, are facing increasing healthcare expenses. While the precise cause of polycystic ovarian syndrome remains unknown and no medications have been approved for direct treatment, related conditions like obesity and insulin sensitivity are on the rise.

Expansion of healthcare infrastructure in the United States, along with higher disposable incomes, has contributed to the increasing prominence of the insulin-sensitizing agent drug class. Additional awareness efforts undertaken by the United States government to raise awareness are also responsible for driving market expansion in the country.

What are the Opportunities for Polycystic Ovary Syndrome Treatment Providers in China?

“Focus on Formulation of Heath Policies and Regulations Governing PCOS Treatment”

Attribute	China
Market Value (2024E)	US$ 375 Million
Growth Rate (2024 to 2034)	6% CAGR
Projected Value (2034F)	US$ 675 Million

PCOS prevalence has risen among Chinese women in recent years. In China, a significant percentage of women of reproductive age suffer from PCOS, prompting a need to update national policies and recommendations based on the latest research findings. Consequently, the Chinese market is emerging as a lucrative space for polycystic ovary syndrome treatment providers.

Category-wise Insights

According to the latest report from Fact.MR, a market research and intelligence provider, based on drug class, demand for insulin-sensitizing agents is projected to rise at a CAGR of 4.8% from 2024 to 2034.

Which Drug Class is Widely Preferred by Treatment Providers and Patients Alike?

“Preference for Oral Contraceptives Due to Their Higher Efficacy Compared to Other Medications”

Attribute	Oral Contraceptives
Segment Value (2024E)	US$ 1.31 Billion
Growth Rate (2024 to 2034)	5.2% CAGR
Projected Value (2034F)	US$ 2.19 Billion

Oral contraceptives are commonly utilized in the treatment of polycystic ovary syndrome (PCOS) because these drugs are more effective compared to other available treatments in the market. They are convenient to administer and provide relief within a short timeframe. Women typically favor oral contraceptives. Therefore, oral contraceptives occupy a significant polycystic ovary syndrome market share in 2024.

Which Distribution Channel is Popular in This Market?

“e-Commerce Platforms Offering Convenience of Ordering Medicines with Single Click”

Attribute	e-Commerce
Segment Value (2024E)	US$ 1.22 Billion
Growth Rate (2024 to 2034)	5.4% CAGR
Projected Value (2034F)	US$ 2.05 Billion

In recent years, the proliferation of e-commerce websites has made it easier for patients to purchase their medicines with just a single click. Many people are using these platforms to browse through various supplier options and select ones with favorable ratings. Market players are actively responding to this trend by enhancing their presence on e-commerce websites to cater to the growing demand.

Competitive Environment

Key players in the polycystic ovary syndrome treatment market are producing unique items to improve their worldwide product portfolios. Similarly, several prominent companies in the market are collaborating to accelerate research and development. Several companies are focusing on alliances with other organizations with items in advanced phases of development to allow faster approval and effective distribution channels for their products, contributing to the growth of the polycystic ovary syndrome treatment market.

• In June 2022, Bayer announced the opening of its new Research and Innovation Center at Kendall Square in the United States, expanding the company’s footprint further in one of the world’s most innovative pharmaceutical research and development locations.

Key Segments of PCOS Market Research

• By Drug Class :

  • Oral Contraceptives
  • Insulin-Sensitizing Agents
  • Antidepressants
  • Ornithine Decarboxylase Inhibitors
  • Aromatase Inhibitors & SERMs

• By Distribution Channel :

  • Hospital Pharmacies
  • Drug Stores/OTC
  • e-Commerce
  • Clinics

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Middle East & Africa